MX2016012509A - Composiciones de ciclodextrina y derivados de budesonida y metodos. - Google Patents

Composiciones de ciclodextrina y derivados de budesonida y metodos.

Info

Publication number
MX2016012509A
MX2016012509A MX2016012509A MX2016012509A MX2016012509A MX 2016012509 A MX2016012509 A MX 2016012509A MX 2016012509 A MX2016012509 A MX 2016012509A MX 2016012509 A MX2016012509 A MX 2016012509A MX 2016012509 A MX2016012509 A MX 2016012509A
Authority
MX
Mexico
Prior art keywords
treatment
cyclodextrin
prophylaxis
composition
relates
Prior art date
Application number
MX2016012509A
Other languages
English (en)
Inventor
Tullio Pascal De
Paul Maes
Evrard Brigitte
Cataldo Didier
Dufour Gilles
Original Assignee
Univ Liege
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Liege filed Critical Univ Liege
Publication of MX2016012509A publication Critical patent/MX2016012509A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Polymers & Plastics (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas novedosas y útiles formuladas con un compuesto de ciclodextrina y un derivado de budesonida para el tratamiento y/o prevención de la enfermedad pulmonar inflamatoria. La presente invención también se refiere a una técnica analítica útil y novedosa para la detección y la cuantificación de HP-ß-CD en solución. Más específicamente, la presente invención se refiere al uso de un análisis de 1H NMR validado para la detección y cuantificación de ciclodextrinas directamente en formulaciones farmacéuticas sin algunas etapas de extracción o separación para formulaciones líquidas.
MX2016012509A 2014-03-28 2015-03-30 Composiciones de ciclodextrina y derivados de budesonida y metodos. MX2016012509A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461972209P 2014-03-28 2014-03-28
EP14162158.1A EP2923702A1 (en) 2014-03-28 2014-03-28 Composition of cyclodextrin with budesonide derivatives for treatment and prevention of pulmonary inflammatory disease
PCT/EP2015/056929 WO2015144938A2 (en) 2014-03-28 2015-03-30 Cyclodextrin and budesonide derivative compositions and methods

Publications (1)

Publication Number Publication Date
MX2016012509A true MX2016012509A (es) 2017-07-04

Family

ID=50389899

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012509A MX2016012509A (es) 2014-03-28 2015-03-30 Composiciones de ciclodextrina y derivados de budesonida y metodos.

Country Status (13)

Country Link
US (1) US9993487B2 (es)
EP (2) EP2923702A1 (es)
JP (1) JP2017509709A (es)
CN (1) CN113144215A (es)
AU (2) AU2015238174A1 (es)
CA (1) CA2944080A1 (es)
MA (1) MA39407A1 (es)
MX (1) MX2016012509A (es)
RU (1) RU2722414C2 (es)
SG (1) SG11201608075VA (es)
TW (1) TWI725935B (es)
UA (1) UA123894C2 (es)
WO (1) WO2015144938A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4122469A1 (en) * 2014-03-28 2023-01-25 Paul Maes Composition comprising cyclodextrin and budesonide derivatives for the treatment and prophylaxis of pulmonary inflammations
BE1027425B1 (fr) 2019-07-01 2021-02-08 Aquilon Pharmaceuticals Composition inhalable comprenant de la cyclodextrine a utiliser dans le traitement d’inflammations nasales
BE1027612B1 (fr) * 2019-09-10 2021-05-03 Aquilon Pharmaceuticals Microparticules en forme de balle de golf pour une utilisation dans le traitement et la prevention de maladies pulmonaires
CN113457468B (zh) * 2021-06-24 2022-10-28 北京工业大学 一种单宁酸-羟丙基β环糊精复合纳滤膜及其制备方法
WO2023118014A1 (en) 2021-12-20 2023-06-29 Aquilon Pharmaceuticals Inhalable compositions comprising a complex of hpbcd and budesonide or ciclesonide for the treatment or prevention of a respiratory viral disease or lipopolysaccharide-induced inflammation, in particular lipopolysaccharide-induced inflammation associated with a respiratory viral disease
BE1030002B1 (fr) 2021-12-29 2023-09-01 Aquilon Pharmaceuticals Compositions inhalables comprenant un complexe de hpbcd et de budesonide ou ciclesonide pour le traitement ou la prevention d'une maladie virale respiratoire

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681828A (en) * 1995-12-19 1997-10-28 Pitha; Josef Selective alkylations of cyclodextrins leading to derivatives which have a rigidly extended cavity
BRPI0418386A (pt) * 2003-12-31 2007-05-22 Cydex Inc formulação inalante contendo éter sulfoalquìlico gama-ciclodextrina e corticosteróide
US9034846B2 (en) 2004-10-10 2015-05-19 Universite De Liege Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases
EP1655034A1 (en) * 2004-10-10 2006-05-10 Université de Liège Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases.
EP1973550A2 (en) * 2005-12-20 2008-10-01 Tika Läkemedel AB Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
EP1894559A1 (en) * 2006-09-01 2008-03-05 PARI Pharma GmbH Means to solubilise steroids for inhalation
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
PT2173169E (pt) * 2007-06-28 2014-09-03 Cydex Pharmaceuticals Inc Entrega nasal de soluções de corticosteróide aquosas
EP2100599A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
WO2015109201A1 (en) 2014-01-17 2015-07-23 Nephron Pharmaceuticals Corporation Budesonide cyclodextrin formulation

Also Published As

Publication number Publication date
RU2016138795A3 (es) 2019-02-07
CN113144215A (zh) 2021-07-23
RU2722414C2 (ru) 2020-05-29
CA2944080A1 (en) 2015-10-01
MA39407A1 (fr) 2017-09-29
SG11201608075VA (en) 2016-10-28
JP2017509709A (ja) 2017-04-06
RU2016138795A (ru) 2018-05-03
EP3151836A2 (en) 2017-04-12
TW201625265A (zh) 2016-07-16
AU2020205304B2 (en) 2023-04-27
AU2020205304A1 (en) 2020-08-06
WO2015144938A2 (en) 2015-10-01
TWI725935B (zh) 2021-05-01
EP3151836B1 (en) 2023-03-08
UA123894C2 (uk) 2021-06-23
WO2015144938A3 (en) 2016-03-31
AU2015238174A1 (en) 2016-10-20
EP2923702A1 (en) 2015-09-30
US9993487B2 (en) 2018-06-12
US20160051568A1 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
MX2016012509A (es) Composiciones de ciclodextrina y derivados de budesonida y metodos.
MX2021015106A (es) Inhibidores de ferroportina novedosos.
PH12017500941A1 (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
BR112016024357A2 (pt) composições de insulina de ação rápida
MY192717A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
EP3337782A4 (en) DIACEREIN OR ITS ANALOGUES FOR INHIBITING THE EXPRESSION OF ASC AND NLRP3 PROTEINS, AND / OR THE FORMATION OF THE INFLAMMASOME COMPLEX NLRP3
MX2016002241A (es) Alcoholes de alquinilo y metodos de uso.
WO2014151456A3 (en) Treatment of inflammatory diseases
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
EP3288389A4 (en) Use of oligosaccharide compositions to enhance weight gain
MX2017007377A (es) Compuestos organicos.
WO2016013030A3 (en) Hydroxysteroid compounds, their intermediates, process of preparation, composition and uses thereof
EP3225241A4 (en) Agent for preventing or improving symptoms caused by imbalance of sex hormones
WO2016092561A3 (en) Novel polymorphs of ivacaftor, process for its preparation and pharmaceutical composition thereof
EP3149192A4 (en) Methods and compositions for use of neutrophil elastase and proteinase 3 as diagnostic biomarkers
IN2014DN06662A (es)
EP3252067A4 (en) Sugar moiety silyl ether derivative of 5-azacytidine
WO2015052568A3 (en) Solid forms of curcumin and derivatives thereof
MA40332A (fr) Réduction des niveaux de cétone alpha, beta-insaturée dans des compositions de dérivés de morphinane
CL2017000560A1 (es) Fórmula que incluye glicopirrolato, método y sistema
MX2018007724A (es) Composicion farmaceutica para tratamiento de hiperplasia prostatica.
MX2020004223A (es) Composiciones de ciclodextrina y derivados de budesonida y metodos.
FR3030523B1 (fr) Nouveaux composes de la famille des n-acylamino-amides,compositions les comprenant, et utilisations

Legal Events

Date Code Title Description
FG Grant or registration